Prediction of Cardiovascular Disease Events

Cardiology Clinics

Volumn 29, Issue 1, 2011, Pages 1-13

  Wilson, Peter W F ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Biomarkers; Coronary heart disease; Prediction; Risk factors

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; LIPID; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE;

ALGORITHM; ATHEROSCLEROSIS; CALIBRATION; CARDIOVASCULAR RISK; CLASSIFICATION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; INCIDENCE; LIPIDS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH;

EID: 78751639862     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.10.004     Document Type: Review

References (93)

1. Walker S.H., Duncan D.B. Estimation of the probability of an event as a function of several independent variables. Biometrika 1967, 54:167-179.
2. Truett J., Cornfield J., Kannel W.B. A multivariate analysis of risk of coronary heart disease in Framingham. J Chronic Dis 1967, 20:511-524.
3. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
4. Schlesselman J.J. Case-control studies 1982, Oxford, New York. 1 edition.
5. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
6. Lipid Research Clinics Population Studies Data book: volume 1. The Prevalence Study 1980 (NIH Publ 80-1527) 1990, NIH, Bethesda (MD). 1st edition.
7. Lipid Research Clinics Program Manual of laboratory operation 1974, NIH, Bethesda (MD). 1st edition.
8. Rifkind B.M., Segal P. Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia. JAMA 1983, 250:1869-1872.
9. Warnick G.R., Myers G.L., Cooper G.R., et al. Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin Chem 2002, 48:11-17.
10. McNamara J.R., Leary E.T., Ceriotti F., et al. Point: status of lipid and lipoprotein standardization. Clin Chem 1997, 43:1306-1310.
11. Myers G.L., Cooper G.R., Sampson E.J. Traditional lipoprotein profile: clinical utility, performance requirement, and standardization. Atherosclerosis 1994, 108(Suppl):S157-S169.
12. Cooper G.R., Myers G.L., Smith J., et al. Blood lipid measurements: variations and practical utility. JAMA 1992, 267:1652-1660.
13. Cooper G.R., Smith S.J., Myers G.L., et al. Estimating and minimizing effects of biologic sources of variation by relative range when measuring the mean of serum lipids and lipoproteins. Clin Chem 1994, 40:227-232.
14. National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979, 28:1039-1057.
15. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
16. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002, 105:310-315.
17. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
18. Wolf P.A., D'Agostino R.B., Belanger A.J., et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991, 3:312-318.
19. Murabito J.M., D'Agostino R.B., Silbershatz H., et al. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation 1997, 96:44-49.
20. Butler J., Kalogeropoulos A., Georgiopoulou V., et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008, 1:125-133.
21. Anderson K.M., Odell P.M., Wilson P.W.F., et al. Cardiovascular disease risk profiles. Am Heart J 1991, 121:293-298.
22. Kannel W.B., Castelli W.P., Gordon T., et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med 1971, 74:1-12.
23. Wilson P.W.F., Castelli W.P., Kannel W.B. Coronary risk prediction in adults: the Framingham Heart Study. Am J Cardiol 1987, 59(G):91-94.
24. Anderson K.M., Wilson P.W.F., Odell P.M., et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991, 83:357-363.
25. Joint National Committee The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 1993, 153:154-183.
26. D'Agostino R.B., Grundy S., Sullivan L.M., et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
27. Grundy S.M., D'Agostino Sr R.B., Mosca L., et al. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation 2001, 104:491-496.
28. Cox D.R. Regression models and life tables. J R Stat Soc (B) 1972, 34:187-220.
29. Pencina M.J., D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123.
30. D'Agostino R.B., Nam B.H. Evaluation of the performance of survival analysis models: discrimination and calibration measures. Handbook of statistics, vol 23: advances in survival analysis 2004, Elsevier, Amsterdam (Netherlands), p. 1-26. 1st edition.
31. Liu J., Hong Y., D'Agostino R.B., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004, 291:2591-2599.
32. Diamond G.A., Hirsch M., Forrester J.S., et al. Application of information theory to clinical diagnostic testing. The electrocardiographic stress test. Circulation 1981, 63:915-921.
33. Wilson P.W., Nam B.H., Pencina M., et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham heart study. Arch Intern Med 2005, 165:2473-2478.
34. Cook N.R., Buring J.E., Ridker P.M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006, 145:21-29.
35. Pepe M.S., Thompson M.L. Combining diagnostic test results to increase accuracy. Biostatistics 2000, 1:123-140.
36. Pepe M.S., Janes H., Longton G., et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159:882-890.
37. Pencina M.J., D'Agostino R.B., D'Agostino R.B., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
38. Stevens R.J., Kothari V., Adler A.I., et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001, 101:671-679.
39. Ferrario M., Chiodini P., Chambless L.E., et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 2005, 34:413-421.
40. Wu Y., Liu X., Li X., et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 2006, 114:2217-2225.
41. de Lemos J.A., Morrow D.A. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application?. Circulation 2002, 106:2868-2870.
42. Blankenberg S., Zeller T., Saarela O., et al. Contribution of 30 Biomarkers to 10-Year cardiovascular risk estimation in 2 population cohorts: the MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project. Circulation 2010, 121:2388-2397.
43. Folsom A.R., Chambless L.E., Ballantyne C.M., et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006, 166:1368-1373.
44. Thompson S.G., Kienast J., Pyke S.D., et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332:635-641.
45. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
46. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
47. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108-1113.
48. Shai I., Rimm E.B., Hankinson S.E., et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004, 110:2824-2830.
49. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation 1999, 99:2517-2522.
50. Jiang R., Schulze M.B., Li T., et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004, 27:1991-1997.
51. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776-785.
52. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512-1524.
53. Maciejko J.J., Holmes D.R., Kottke B.A., et al. Apolipoprotein A-I as a marker of angiographically assessed coronary artery disease. N Engl J Med 1983, 309:385-389.
54. van Lennep J.E., Westerveld H.T., van Lennep H.W., et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000, 20:2408-2413.
55. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26:847-870.
56. Festa A., Williams K., Hanley A.J., et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005, 111:3465-3472.
57. Cromwell W., Otvos J.D., Keyes M.J., et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management. J Clin Lipidol 2007, 1:583-592.
58. Bostom A.G., Cupples L.A., Jenner J.L., et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996, 276:544-548.
59. Scanu A.M. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep 2003, 5:106-113.
60. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46-57.
61. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
62. Ridker P.M., Brown N.J., Vaughan D.E., et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004, 109:IV6-19.
63. Wilson P.W.F., Pencina M., Jacques P., et al. C-Reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008, 1:92-97.
64. Ridker P.M., Paynter N.P., Rifai N., et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008, 118:2243-2251. 4p.
65. Ridker P.M., Buring J.E., Rifai N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611-619.
66. Oei H.H., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570-575.
67. Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005, 25:923-931.
68. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
69. Sabatine M.S., Morrow D.A., O'Donoghue M., et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007, 27:2463-2469.
70. Garza C.A., Montori V.M., McConnell J.P., et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007, 82:159-165.
71. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2005, 165:2479-2484.
72. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol: modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
73. Glass C.K., Witztum J.L. Atherosclerosis. The road ahead. Cell 2001, 104:503-516.
74. McCord J.M. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985, 312:159-163.
75. Podrez E.A., Schmitt D., Hoff H.F., et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999, 103:1547-1560.
76. Holvoet P., Harris T.B., Tracy R.P., et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition Study. Arterioscler Thromb Vasc Biol 2003, 23:1444-1448.
77. Holvoet P., Vanhaecke J., Janssens S., et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98:1487-1494.
78. Holvoet P., Theilmeier G., Shivalkar B., et al. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. Arterioscler Thromb Vasc Biol 1998, 18:415-422.
79. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001, 103:1955-1960.
80. Holvoet P., Kritchevsky S.B., Tracy R.P., et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004, 53:1068-1073.
81. Morrow D.A., Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003, 108:250-252.
82. Morrow D.A., Sabatine M.S., Brennan M.L., et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008, 29:1096-1102.
83. Meuwese M.C., Stroes E.S., Hazen S.L., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 50:159-165.
84. Omland T., de Lemos J.A., Sabatine M.S., et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009, 361:2538-2547.
85. Januzzi J.L., Bamberg F., Lee H., et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010, 121:1227-1234.
86. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
87. Califf R.M., Armstrong P.W., Carver J.R., et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996, 27:1007-1019.
88. Eagle K.A., Lim M.J., Dabbous O.H., et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004, 291:2727-2733.
89. Mainous A.G., Koopman R.J., Diaz V.A., et al. A coronary heart disease risk score based on patient-reported information. Am J Cardiol 2007, 99:1236-1241.
90. Gaziano T.A., Young C.R., Fitzmaurice G., et al. Laboratory-based versus nonlaboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008, 371:923-931.
91. Detrano R., Guerci A.D., Carr J.J., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358:1336-1345.
92. Humphries S.E., Yiannakouris N., Talmud P.J. Cardiovascular disease risk prediction using genetic information (gene scores): is it really informative?. Curr Opin Lipidol 2008, 19:128-132.
93. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.